Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Пятилетние результаты лечения дабрафенибом в комбинации с траметинибом при метастатической меланоме
Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy, Bogusława Karaszewska, Axel Hauschild, E. Levchenko, Vanna Chiarion‐Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko, Helen J Gogas, Mario Mandalà, John B.A.G. Haanen, Célèste Lebbé, Andrzej Adam Mackiewicz, Piotr Lukasz Rutkowski, Paul Nathan, Antoni Ribas, Michael A. Davies, Keith T. Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, Maurizio Voi, Dirk Schadendorf, Georgina Venetia Long
2019-06-04

BRAF V600E/V600K mutationsCOMBI-d and COMBI-v trialsDabrafenib plus trametinibFive-year overall survivalMetastatic melanoma
BACKGROUND: V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors. However, long-term clinical outcomes in these patients remain undefined. To determine 5-year survival rates and clinical characteristics of the patients with durable benefit, we sought to review long-term data from randomized trials of combination therapy with BRAF and MEK inhibitors. METHODS: We analyzed pooled extended-survival data from two trials involving previously untreated patients who had received BRAF inhibitor dabrafenib (at a dose of 150 mg twice daily) plus MEK inhibitor trametinib (2 mg once daily) in the COMBI-d and COMBI-v trials. The median duration of follow-up was 22 months (range, 0 to 76). The primary end points in the COMBI-d and COMBI-v trials were progression-free survival and overall survival, respectively. RESULTS: A total of 563 patients were randomly assigned to receive dabrafenib plus trametinib (211 in the COMBI-d trial and 352 in the COMBI-v trial). The progression-free survival rates were 21% (95% confidence interval [CI], 17 to 24) at 4 years and 19% (95% CI, 15 to 22) at 5 years. The overall survival rates were 37% (95% CI, 33 to 42) at 4 years and 34% (95% CI, 30 to 38) at 5 years. In multivariate analysis, several baseline factors (e.g., performance status, age, sex, number of organ sites with metastasis, and lactate dehydrogenase level) were significantly associated with both progression-free survival and overall survival. A complete response occurred in 109 patients (19%) and was associated with an improved long-term outcome, with an overall survival rate of 71% (95% CI, 62 to 79) at 5 years. CONCLUSIONS: V600E or V600K mutation. (Funded by GlaxoSmithKline and Novartis; COMBI-d ClinicalTrials.gov number, NCT01584648; COMBI-v ClinicalTrials.gov number, NCT01597908.).
1
Baseline performance status, age, sex, number of metastatic organ sites, and lactate dehydrogenase levels were significantly associated with progression-free and overall survival.
2
Complete response occurred in 19% of patients and was associated with substantially better long-term survival, reaching 71% overall survival at five years.
3
Pooled five-year data from COMBI-d and COMBI-v evaluated first-line dabrafenib plus trametinib in 563 patients with metastatic melanoma.
4
Progression-free survival was 19% at five years, while overall survival was 34% at five years after combination therapy.
5
The analysis defined durable benefit and long-term outcomes for patients with V600E or V600K-mutant metastatic melanoma receiving BRAF and MEK inhibition.

Previously untreated patients with metastatic melanoma harboring BRAF V600E or V600K mutations treated with dabrafenib plus trametinib

Five-year progression-free and overall survival outcomes and baseline clinical characteristics associated with durable benefit from combined BRAF and MEK inhibition

Publication Details
Publication Date
2019-06-04
Journal
New England Journal of Medicine
Publisher
Massachusetts Medical Society
ISSN
0028-4793
Cited by
1516
Access Type
Author Information
Authors
Caroline Robert
Jean‐Jacques Grob
Daniil Stroyakovskiy
Bogusława Karaszewska
Axel Hauschild
E. Levchenko
Vanna Chiarion‐Sileni
Jacob Schachter
Claus Garbe
Igor Bondarenko
Helen J Gogas
Mario Mandalà
John B.A.G. Haanen
Célèste Lebbé
Andrzej Adam Mackiewicz
Piotr Lukasz Rutkowski
Paul Nathan
Antoni Ribas
Michael A. Davies
Keith T. Flaherty
Paul Burgess
Monique Tan
Eduard Gasal
Maurizio Voi
Dirk Schadendorf
Georgina Venetia Long
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%